CollPlant Biotechnologies (CLGN) EPS (Basic) (2017 - 2026)
CollPlant Biotechnologies' (CLGN) quarterly EPS (Basic) came in at -$2.55 in Q1 2026, down 77.41% on a YoY basis from -$11.3 in Q1 2025, and up 1.11% quarter-over-quarter from -$2.58 in Q4 2025.
Powered by 
Analysis
CollPlant Biotechnologies (CLGN) EPS (Basic) (2017 - 2026) Analysis & Trends
CollPlant Biotechnologies (CLGN) has reported EPS (Basic) for 10 consecutive years, with -$2.55 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, EPS (Basic) fell 77.41% year-over-year to -$2.55; the trailing twelve-month figure through Mar 2026 stood at -$5.4 (down 7.49% YoY), and the FY2025 full-year result was -$9.1, up 36.89% from the prior year.
- EPS (Basic) rose to -$2.55 in Q1 2026 per CLGN's latest filing, from -$2.58 in the prior quarter.
- Across five years, EPS (Basic) topped out at $5.15 in Q2 2023 and bottomed at -$4.48 in Q3 2022.
- Historically, EPS (Basic) has averaged -$0.95 across 5 years, with a median of -$2.58 in 2025.
- The sharpest annual moves came in 2023 and 2025: EPS (Basic) surged 222.57% in 2023, then slumped 137.85% in 2025.
- Over 5 years, EPS (Basic) stood at -$4.24 in 2022, then slipped by 5.0% to -$4.45 in 2023, then increased by 22.03% to -$3.47 in 2024, then climbed by 25.6% to -$2.58 in 2025, then advanced by 1.11% to -$2.55 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$2.55, -$2.58, and -$3.06 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -0.40 |
| 10 | CollPlant Biotechnologies | 4.17 Mn | 4.17 Mn | -243,000.00 | -2.55 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 30, 2026 | -2.55 |
| Dec 31, 2025 | -2.58 |
| Sep 30, 2025 | -3.06 |
| Jun 30, 2025 | 2.77 |
| Mar 30, 2025 | -1.44 |
| Dec 31, 2024 | -3.47 |
| Sep 30, 2024 | -3.99 |
| Jun 30, 2024 | 3.87 |
| Mar 31, 2024 | 3.80 |
| Dec 31, 2023 | -4.45 |
| Sep 30, 2023 | -4.17 |
| Jun 30, 2023 | 5.15 |
| Mar 31, 2023 | 3.19 |
| Dec 31, 2022 | -4.24 |
| Sep 30, 2022 | -4.48 |
| Jun 30, 2022 | -4.20 |
| Mar 31, 2022 | 3.78 |
| Dec 31, 2021 | -3.79 |
| Sep 30, 2021 | -4.38 |
| Jun 30, 2021 | -4.33 |